Liraglutide Safety Profile
FDA-approved GLP-1 agonist with extensive clinical safety data. Common GI side effects. Boxed warning for thyroid C-cell tumors (rodent studies).
Last updated: February 12, 2026
For Educational Purposes Only
This safety information is compiled from clinical trial data and regulatory documents for educational purposes. It is not a substitute for professional medical advice. Always consult your healthcare provider about medication safety, especially regarding your individual circumstances, medical history, and other medications.
Safety Overview
Liraglutide is FDA-approved for two indications:
- Victoza (1.8 mg) for type 2 diabetes (2010)
- Saxenda (3.0 mg) for weight management (2014)
Level of evidence: Extensive. Safety data from large randomized trials including LEADER (cardiovascular outcomes, 9,340 patients over 3.8 years) and multiple phase III studies.
Generic launch: First generic versions approved August 2025, with ongoing post-market surveillance.
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 39% (Saxenda trials) | Usually peaks in weeks 1-4, often subsides |
| Diarrhea | 21% | Dose-dependent |
| Vomiting | 16% | May require dose adjustment |
| Constipation | 20% | Paradoxically common despite diarrhea reports |
| Headache | 14% | Generally mild |
| Injection site reactions | 14% | Erythema, itching |
Discontinuation Rate
Approximately 9-13% discontinue due to GI side effects in clinical trials.
Serious Safety Concerns
Thyroid C-Cell Tumors (Boxed Warning)
- Rodent studies showed increased incidence of thyroid C-cell tumors at clinically relevant exposures
- No conclusive evidence in humans as of 2026
- Unknown if liraglutide causes medullary thyroid carcinoma (MTC) in humans
- Monitoring: Routine calcitonin monitoring NOT recommended by FDA
Pancreatitis
- Reports of acute pancreatitis in post-marketing surveillance
- Mechanism uncertain (class effect of GLP-1 agonists remains debated)
- Discontinue if pancreatitis suspected
Gallbladder Disease
- Increased risk of cholelithiasis (gallstones) and cholecystitis
- Likely related to rapid weight loss, not direct drug effect
- Monitor for symptoms: right upper quadrant pain, fever, jaundice
Kidney Injury
- Acute kidney injury reported, often in context of severe GI side effects causing dehydration
- Monitor renal function in patients with renal impairment
- Ensure adequate hydration during treatment
Hypoglycemia
- Low risk when used alone
- Increased risk when combined with insulin or sulfonylureas (dose reduction of these agents often needed)
Contraindications
Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of serious hypersensitivity to liraglutide
Use with caution:
- History of pancreatitis
- Severe renal impairment (limited data)
- Gastroparesis or severe GI disease
Generic and Compounded Versions
Following the August 2025 generic approval, multiple manufacturers now produce liraglutide. Quality concerns include:
- Verify product from FDA-approved manufacturers
- Avoid compounded liraglutide unless from 503B outsourcing facilities (higher regulatory oversight)
- FDA has noted quality issues with some compounded GLP-1 products
This safety information is based on FDA labeling and published clinical trials. It does not constitute medical advice. Liraglutide should only be used under medical supervision. Always consult a healthcare provider for personalized risk assessment.
Safety Alerts
Get notified about new safety data, FDA decisions, and adverse event reports.
No spam. Unsubscribe anytime.
Important: Safety information evolves as post-marketing data accumulates. This page reflects data available as of the last update date. Check official FDA and EMA resources for the most current safety information. This content is not intended to diagnose, treat, cure, or prevent any disease.